Literature DB >> 3968978

Physiological plasma concentrations of cholecystokinin stimulate pancreatic enzyme secretion and gallbladder contraction in man.

P J Kerstens, C B Lamers, J B Jansen, A J de Jong, M Hessels, J C Hafkenscheid.   

Abstract

The present study was undertaken to determine whether infusion of cholecystokinin (CCK) to plasma concentrations comparable to those found after a meal stimulates pancreatic enzyme secretion and gallbladder contraction. Plasma CCK concentrations were measured by radioimmunoassay using antibody T204, which binds to all carboxyl-terminal CCK-peptides containing the sulfated tyrosine region. Ingestion of a standardized test meal in 7 normal subjects induced significant increases in plasma CCK from 2.0 +/- 0.2 pmol/l to levels between 4.6 +/- 0.6 and 7.3 +/- 1.0 pmol/l (p less than 0.05-p less than 0.0005). Infusion of 2.5 pmol/kg X h CCK 33 resulted in significant increases in plasma CCK from 2.0 +/- 0.2 to 3.9 +/- 0.3 pmol/l (p less than 0.0005). This infusion of CCK induced significant increases in trypsin secretion from 0.5 +/- 0.1 to 1.4 +/- 0.2 KU/15 min (p less than 0.005) and in bilirubin output from 1.6 +/- 0.7 to 30.3 +/- 8.0 mumol/15 min (p less than 0.05). It is concluded that physiological plasma concentrations of CCK stimulate pancreatic enzyme secretion and gallbladder contraction in man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3968978     DOI: 10.1016/0024-3205(85)90638-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

Review 1.  Personalizing protein nourishment.

Authors:  David C Dallas; Megan R Sanctuary; Yunyao Qu; Shabnam Haghighat Khajavi; Alexandria E Van Zandt; Melissa Dyandra; Steven A Frese; Daniela Barile; J Bruce German
Journal:  Crit Rev Food Sci Nutr       Date:  2017-10-13       Impact factor: 11.176

2.  The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.

Authors:  Helen H Wang; Piero Portincasa; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2016-01-12       Impact factor: 4.686

3.  Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.

Authors:  B E Evans; M G Bock; K E Rittle; R M DiPardo; W L Whitter; D F Veber; P S Anderson; R M Freidinger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  The significance of plasma CCK and secretin in the oleate-stimulated pancreatico-biliary secretion in man.

Authors:  O Olsen; O B Schaffalitzky de Muckadell; P Cantor
Journal:  Int J Pancreatol       Date:  1986-12

Review 5.  Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor.

Authors:  Erin E Cawston; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

Review 6.  Cholecystokinin-From Local Gut Hormone to Ubiquitous Messenger.

Authors:  Jens F Rehfeld
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-13       Impact factor: 5.555

7.  Sensitivity of cholecystokinin receptors to membrane cholesterol content.

Authors:  Aditya J Desai; Laurence J Miller
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-18       Impact factor: 5.555

Review 8.  Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion.

Authors:  Van B Lu; Fiona M Gribble; Frank Reimann
Journal:  Nutrients       Date:  2021-03-09       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.